Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Nivolumab Plus Gemcitabine in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma-HN17-11

NCT06440187 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT06440187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06440187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Nivolumab Plus Gemcitabine in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma-HN17-11
Lead sponsor
Seoul National University Hospital
Phase
Phase 2
Overall status
Completed
Start date
June 8, 2018
Completion date
April 30, 2021
Enrollment
38 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent or metastatic nasopharyngeal carcinom